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Objective: Adverse metabolic changes associated with loss of ovarian function increase the risk of developing
metabolic syndrome and non-alcoholic fatty liver disease (NAFLD) in postmenopausal women. Naringenin improves
metabolic disturbances in vitro and in vivo. In the present study, we tested the effects of naringenin on metabolic
disturbances resulting from estrogen deficiency in ovariectomized mice.
Materials/methods: Ovariectomized C57BL/6 J female mice were fed a control diet (10% calories from fat) for
11 weeks. Mice either continued on the control diet (n = 9) or were switched to the control diet supplemented with 3%
naringenin (n = 10) for the next 11 weeks. Energy expenditure was measured by indirect calorimetry and activity was
monitored by infrared beam breaks. Intra-abdominal and subcutaneous adiposity was evaluated by magnetic resonance
imaging (MRI). Blood biochemical measures of metabolic response included glucose, insulin, adipokines, and lipids. Lipid
content in liver and muscle and expression of relevant genes in adipose tissue, liver, and muscle were quantified.
Results: Ovariectomized mice fed naringenin exhibited lower fasting glucose and insulin levels compared to
controls, with over 50% reduction of intra-abdominal and subcutaneous adiposity. Plasma leptin and leptin
mRNA in adipose depots were also decreased in mice fed a naringenin diet. Monocyte chemoattractant protein-1
(MCP1/Ccl2) and interleukin 6 (IL-6/Il6) mRNA expression levels were significantly lower in perigonadal adipose
tissue of naringenin-supplemented mice. We also observed that mice fed a naringenin diet had less hepatic lipid
accumulation with corresponding alterations of hepatic gene expression associated with de novo lipogenesis, fatty
acid oxidation, and gluconeogenesis.
Conclusion: Dietary naringenin attenuates many of the metabolic disturbances associated with ovariectomy in
female mice.
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During menopause, many women experience weight
gain and accumulation of body fat in the waist region
[1]. These changes of body composition increase the risk
of developing metabolic syndrome [2], non-alcoholic fatty
liver disease [3], and heart disease [4]. Although exogen-
ous estrogen has been shown to be protective against* Correspondence: Belury.1@osu.edu
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term usage of hormone replacement therapy may increase
the risk of breast cancer in addition to negative implica-
tions for cardiovascular diseases in postmenopausal
women [5]. Lifestyle changes to reduce body weight, in-
cluding healthy diet and regular exercise, are the initial
strategies recommended for prevention and treatment
of menopause-related metabolic disturbances.
Biologically active phytochemicals have attracted con-
siderable attention for their potential health-promoting
benefits [6,7]. Naringenin is a flavonoid that is abundant
in citrus fruits and tomatoes [8,9]. Previously, we foundis an Open Access article distributed under the terms of the Creative Commons
rg/licenses/by/4.0), which permits unrestricted use, distribution, and
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medicine used for treating type 2 diabetes, to reduce hep-
atic glucose production in hepatocytes [10]. In addition,
naringenin improved some aspects of glucose and lipid
homeostasis and mitigated adipose tissue inflammation
in vivo [10-15]. However, the effects of naringenin on adi-
pose depot mass and metabolic abnormalities associated
with estrogen deficiency have not been studied.
Metabolic changes induced by estrogen depletion from
ovariectomy share many similar characteristics with
changes in menopausal women that are independent of
energy intake, e.g., weight gain, increased adiposity, adipose
tissue inflammation, and the development of fatty liver
with inflammation [16,17]. These similarities make ovariec-
tomized mice a good model to study physiological changes
after menopause. Therefore, in the present study we inves-
tigated the effect of 3% wt/wt naringenin supplementation
in female ovariectomized (OVX) mice. The aim of our
study is to determine whether naringenin ameliorates
weight gain and attenuates accumulation of subcutaneous
and abdominal adipose tissues, with resultant decreases in
fasting glucose and ectopic lipid accumulation in muscle
and liver of OVX mice. Our findings suggest that many of
the effects of naringenin on dysregulated metabolism are
related to effects of reduced adipose mass and ectopic




Twenty-week old C57BL/6 J female mice were ovariecto-
mized at 19 weeks old (Jackson Laboratory; Bar Harbor,
ME, USA) and housed 4–5 per cage at 22 ± 0.5°C on a
12:12-h light–dark cycle. After 2 weeks of acclimation,
mice (n = 19) were fed ad libitum a semi-purified diet for
11 weeks to enhance weight gain (D12450J, Research
Diets Inc. New Brunswick, NJ, USA, formula is shown
in Additional file 1: Table S1). Then mice were random-
ized by weight into either CON (n = 9) or NAR (n = 10)
group (randomization was based on 19 mice as one mouse
died prior to assignment to diet groups). For the next
11 weeks, the CON group continued on the control diet
and the NAR group received the control diet supple-
mented with 3% wt/wt naringenin (Sigma, St. Louis, MO,
USA), custom prepared by Research Diets Inc. (formula is
shown in Additional file 1: Table S1). This dose of narin-
genin is based on a previously published study showing
amelioration of metabolic disturbances in C57BL/6 J male
mice fed a high-fat diet with 3% naringenin [12]. Body
weight and food intake were measured daily. At week 22,
mice were fasted for 5 h, anesthetized with isoflurane for
blood collection via cardiac puncture, and then euthanized
by cervical dislocation. Blood was collected into EDTA-
coated blood collection tubes and plasma was obtainedafter centrifugation. Tissues, including subcutaneous adi-
pose tissue (SCAT, thoracic and abdominal mammary fat
pads), liver, perigonadal adipose tissue (PGAT), and quad-
riceps skeletal muscle, were excised, weighed, snap frozen
in liquid nitrogen, and stored at −80°C until further ana-
lysis. All procedures were in accordance with institution
guidelines and approved by the Institutional Animal Care
and Use Committee at The Ohio State University.
Fasting glucose analysis
At weeks 5 and 18, glucose was measured from tail vein
blood samples after a 5 h period of fasting (OneTouch
Ultra blood glucose meter, LifeScan Inc., Milpitas, CA,
USA).
Plasma analysis
Plasma insulin, leptin, and adiponectin levels were
measured by ELISA (Millipore, Billerica, MA, USA) ac-
cording to the manufacturer’s instructions. Plasma triglyc-
erides were examined using a Cholestech LDX analyzer
(Cholestech Corporation, Hayward, CA, USA). Plasma
free fatty acids (NEFA C, Wako Chemicals, Richmond,
VA, USA) and total cholesterol (Pointe Scientific Inc.,
Canton, MI, USA) were determined by enzymatic col-
orimetric assays.
Indirect calorimetry
During week 17, six mice in each group were housed
individually in metabolic chambers at 22°C, allowed
free access to food and water, and acclimated 24 hours
prior to metabolic assessments. Measurements were
taken for a 24-h period, including a 12-h light cycle and
a 12-h dark cycle. Oxygen consumption (VO2), carbon
dioxide production (VCO2), and physical activity (by infra-
red beam breaks) were measured every 20 minutes using
a computer-controlled, open-circuit Oxymax/CLAMS
System (Columbus Instruments, Columbus, OH, USA).
Respiratory exchange ratio (RER) was calculated as the ra-
tio of VCO2 to VO2. Heat, the standard measure of energy
expenditure, was calculated with the formula [18],
Heat kcal=hrð Þ ¼ 3:815 þ 1:232  RERð Þ VO2ð Þ
1L=1000 ml  1kg=1000 gð Þ body weightð Þ
Magnetic Resonance Imaging (MRI)
During week 19, total, intra-abdominal, and subcutaneous
adiposity were analyzed by MRI using a Bruker Biospin
94/30 magnet (Billerica, MA, USA) and a 70 mm diameter
linear volume coil. T1-weighted coronal images of the
whole mouse torso were collected using a respiratory-
gated RARE sequence (TR/TE = 1570/7.5 ms, RARE fac-
tor = 4, FOV = 70×45 mm2, matrix size = 256×192, slice
Ke et al. Nutrition & Metabolism 2015, 12:1 Page 3 of 10
http://www.nutritionandmetabolism.com/content/12/1/1thickness = 1 mm, navg = 2). The details and definition of
fat areas are shown in Additional file 1: Figure S1.
Histology
Liver samples were collected at necropsy and fixed in 10%
neutral buffered formalin overnight and transferred to 70%
ethanol for storage. Tissues were then processed, embedded
in paraffin, sectioned, and stained with hematoxylin and
eosin (H&E).
Total lipids, triacylglyceride and diacylglyceride analysis
of liver and muscle
Total lipids were extracted from liver or muscle samples
with 2:1 (v/v) chloroform: methanol and washed with
0.88% KCL [19]. The chloroform phase was transferred
to a weighed test tube and dried under nitrogen gas at
room temperature. The test tube containing the dried
sample was weighed again to calculate total extracted
lipid. Following the lipid extraction, triacylglycerol and
diacylglycerol were obtained using solid-phase extraction
[20] and solubilized in tert-butanol, methanol, Triton
X-100 [21]. Analysis was performed using enzymatic
colorimetric assay [22].
RNA extraction and quantitative real-time polymerase
chain reaction (qRT-PCR) analysis of gene expression
Total RNA was extracted from liver and muscle samples
with QIAzol lysis reagent (Qiagen, Valencia, CA, USA) and
from perigonadal adipose tissue and subcutaneous adipose
tissue using RNeasy Lipid Tissue Mini Kit (Qiagen) follow-
ing manufacturer’s instructions. Total RNA was then re-
versed transcribed to cDNA using High Capacity cDNA
Reverse Transcription Kit (Applied Biosystems, Foster City,
CA, USA). qRT-PCR analysis was performed with ABI
Prism 7300 sequence detection system (Applied Biosys-
tems) using TaqMan Gene Expression Assays (Applied
Biosystems, Additional file 1: Table S2). Target gene ex-
pression was normalized to 18S rRNA for perigonadal
adipose tissue or glyceraldehyde 3-phosphate dehydro-
genase (GAPDH) for liver, subcutaneous adipose tissue,
and muscle. Endogenous Controls (VIC probes) were
amplified in the same reaction and expressed as 2-ΔΔCt
compared to the CON group [23].
Statistical analysis
All data are presented as mean ± standard error (SEM)
with p < 0.05 considered significantly different. Statis-
tical analysis was performed using SPSS version 20.0
software (SPSS, Inc., Chicago, IL, USA). Significance
was determined using two-tailed unpaired Student’s
t test. Caloric intake, heat, and adipose mass were also
analyzed by ANCOVA with body weight as a covariate
[24]. Pearson correlation coefficient was used for the
correlation analyses.Results
Effect of naringenin on caloric intake, body weight, and
metabolic measurements
Caloric intake decreased significantly when mice were
switched to a naringenin-containing diet at week 12
(Figure 1A) without complete recovery to baseline in the
following weeks. However, excluding week 12, daily caloric
intake from week 0–11 to week 13–22 did not differ sig-
nificantly between the two treatment groups (p = 0.075).
Body weights were significantly reduced in the NAR group
from week 12 until the end of the study (Figure 1B). There
were no differences in caloric intake between groups after
adjusting for body weight (ANCOVA, p = 0.508). There
were also no differences in ambulatory activity (Figure 1C)
and energy expenditure after controlling for body weight
differences between groups (Figure 1D).
Fasting glucose levels were significantly elevated in the
CON mice from 121.8 ± 5.8 mg/dl at week 5 to 163.0 ±
5.2 mg/dl at week 18 (Figure 1E), while unchanged in
NAR mice (128.6 ± 4.8 at week 5 and 127.1 ± 10.2 at week
18). Additionally, diets enriched with naringenin resulted
in decreased fasting insulin levels and HOMA-IR values
(Figure 1F & G), surrogate markers of insulin sensitivity.
Using an insulin tolerance test, we observed that glucose
levels were significantly lower in the NAR mice compared
to the CON mice at 45 min (48.0 ± 3.4 mg/dl vs. 64.8 ±
8.1 mg/dl) and 60 min (51.4 ± 8.2 mg/dl vs. 77.0 ± 6.1 mg/
dl) after injection of insulin (Additional file 1: Figure S2).
However, no difference was observed in areas under the
curve (AUC) between groups.
Effect of naringenin on adiposity, plasma adipokines, and
adipose tissue gene expression
MRI analysis was performed in a subset of mice from both
groups (n = 6), which revealed a reduction in total, intra-
abdominal and subcutaneous adiposity by 54, 59, and
50%, respectively, in mice fed naringenin versus control
diets (Figure 2A & C). Additionally, naringenin was sig-
nificantly associated with decreased perigonadal (PGAT)
and subcutaneous (SCAT) adipose tissues (Table 1). Be-
cause body weights differed significantly between groups
and body weight had a significant effect on perigonadal
and subcutaneous adipose tissue mass (p < 0.001), we used
ANCOVA to adjust for this difference when comparing
adipose tissue mass. Mice fed naringenin had significantly
decreased perigonadal adipose tissue mass (p = 0.006)
after controlling for body weight in comparison to con-
trol mice. Fasting plasma leptin levels decreased by 80%
in the NAR mice (Figure 2B) and strongly correlated with
total, intra-abdominal, and subcutaneous adiposity deter-
mined by MRI (total, r = 0.85, p = 0.008; intra-abdominal,
r = 0.86, p = 0.006; subcutaneous, r = 0.80, p = 0.016), as
well as both perigonadal and subcutaneous adipose tissue
mass (r = 0.95 and 0.97 respectively, both p < 0.001).
Figure 1 Effects of dietary naringenin on caloric intake, body weight, and metabolic measurements. OVX C57BL/6 J mice were fed the
control diet for 11 weeks then randomized to continuation of the control diet (n = 9) or switched to 3% wt/wt naringenin supplementation of
the control diet (n = 10) for the weeks 12–22. Average daily caloric intake (A) of two groups (n = 2/group) and weekly body weight (B) of the
CON (n = 9) and NAR (n = 10) group were determined. At week 17, CLAMS chambers were used to measure locomotor activity (ambulation) in
the horizontal plane by infrared beam breaks (C) and estimated energy expenditure (heat) after controlling for body weight (D) in the dark and
light phase for 24-h following a 24-h acclimation (n = 6/group). Fasting glucose levels (E) were measured at week 5 and week 18, (CON, n = 9;
NAR, n = 10). Fasting insulin levels (F) were determined after 22 weeks of experimental period (n = 6/group). HOMA-IR values (G) were derived
from fasting plasma glucose and insulin (n = 4/group). Values are presented as mean ± SEM. Significance between groups was determined by
Student’s t test, except metabolic data of heat was analyzed by ANCOVA with body weight as a covariate. #P < 0.05 compared CON with NAR.
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with insulin levels (r = 0.76, p = 0.004), as previously
shown in women [25]. Dietary naringenin was not asso-
ciated with changes in levels of adiponectin in plasma
and mRNA expression (Adipoq) in perigonadal adipose
tissue between groups (Figure 2B & D). Mice fed narin-
genin also had significantly lower leptin mRNA expres-
sion (Lep) in adipose depots, with a 60% reduction in
perigonadal adipose tissue and a 55% reduction in sub-
cutaneous adipose tissue (Figure 2D & E).
We measured mRNA levels of genes encoding for sev-
eral markers of inflammation related to obesity, including
the chemokine MCP1 (Ccl2), proinflammatory cytokine
IL6 (Il6) and TNFα (Tnf ), and macrophage-specific
marker F4/80 (Emr1) in adipose depots (Figure 2D & E).
The diet with naringenin significantly down-regulated
mRNA levels of MCP1 (56% reduction) and IL6 (40%
reduction) in perigonadal adipose tissue, but had no sig-
nificant effect on MCP1 and IL6 levels in subcutaneous
adipose tissue. TNFα and F4/80 mRNA was not affectedby the naringenin supplementation in perigonadal adi-
pose tissue.
Effect of naringenin on plasma, hepatic, and muscle lipid
profile
Dietary naringenin reduced total cholesterol levels
(Figure 3A), but did not change the levels of triglyceride
and non-esterified fatty acids in plasma (Figure 3B & C).
As ectopic lipid accumulation in liver has been observed
in OVX animals [26], we tested hepatic lipid contents in
both groups. Dietary naringenin decreased the extracted
total lipids and triacylglyceride levels in the liver (Figure 3D
& E) but did not affect diacylglyceride levels (data not
shown). Small lipid droplets were scattered throughout
H&E stained liver sections from the CON group, while no
lipid droplets were detected in the NAR group (Figure 3F).
OVX has been shown to increase muscle lipid contents
[27]. Therefore, we examined muscle lipid levels and
found naringenin reduced the extracted total lipids levels
(Figure 3G) but had no effect on either triacylglyceride
Figure 2 Effects of dietary naringenin on adiposity, plasma adipokines, and adipose tissue gene expression. At week 19, MRI analysis
was performed in a subset of mice (n = 6/group) to measure percentage of total body fat and percentage of two adipose tissue depots,
intra-abdominal and subcutaneous adipose tissues (A). Fasting plasma leptin and adiponectin in the CON (n = 6) and NAR (n = 5-6) groups were
measured at the end of study at 22 weeks (B). Panel (C) shows representative coronal MRI views from each group. Effects of dietary naringenin
on the mRNA levels of genes in perigonadal adipose tissue (D) and in subcutaneous adipose tissue (E) are shown (CON, n = 6-8; NAR, n = 10).
Values are presented as mean ± SEM. Significance between groups was determined by Student’s t test. #P < 0.05 compared CON with NAR.
Table 1 Effect of dietary naringenin on tissue mass in
OVX C57BL/6 J female mice
CON NAR
Tissue Weights (g)
Perigonadal Adipose Tissue 1.44 ± 0.15 0.38 ± 0.05#
Subcutaneous Adipose Tissue 1.21 ± 0.14 0.52 ± 0.03#
Liver 0.94 ± 0.05 0.80 ± 0.03#
Muscle (Quadriceps) 0.36 ± 0.01 0.32 ± 0.02
Tissue Weight Percentages (%)
Perigonadal Adipose Tissue 5.23 ± 0.35 1.81 ± 0.19#
Subcutaneous Adipose Tissue 4.34 ± 0.34 2.55 ± 0.15#
Liver 3.45 ± 0.09 3.89 ± 0.12#
Muscle (Quadriceps) 1.33 ± 0.07 1.55 ± 0.07#
Significance between groups was determined by Student’s t-test (n = 9–10).
Data represent the mean ± SEM.
#P < 0.05 compared NAR with CON.
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(data not shown).
Effect of naringenin on hepatic and muscle mRNA
expression
Srebf1, Fasn, and Scd1 encode proteins involved in de
novo lipogenesis. Increased hepatic expression of Srebf1
was observed in the NAR mice (Figure 4A). However,
naringenin down-regulated Scd1 mRNA by 38% but had
no effect on another lipogenic enzyme, Fasn. No differ-
ences in mRNA levels of genes related to steatotic liver
[28,29] were detected, e.g., Pparg and Dgat2 (Figure 4A).
Expression of genes involved in fatty acid oxidation,
Cpt1α (mitochondrial) was significantly higher in the mice
fed a naringenin diet, but Acox1 (peroxisomal) was de-
creased (Figure 4B). PGC1α (Ppargc1a) is a transcriptional
coactivator regulating genes involved in fatty acid oxida-
tion and gluconeogenesis. Dietary naringenin induced
PGC1α mRNA (4-fold) as well as PEPCK (Pck2) mRNA
(3.5-fold), a rate-limiting enzyme in hepatic gluconeogene-
sis (Figure 4B), but not G6Pase (G6pc) mRNA, another
enzyme involved in gluconeogenesis. Having observed
Figure 3 Effects of dietary naringenin on plasma lipids and lipid accumulation in liver and muscle. Plasma cholesterol (A; CON, n = 6;
NAR, n = 10), triglyceride (B; n = 4/group) and NEFA (C; n = 6/group) after 5-h fasting obtained prior to necropsy were measured by enzymatic
colorimetric method. Total lipids (D; CON, n = 9; NAR n = 9) and triglyceride (E; CON, n = 8; NAR n = 9) per gram of liver section were determined.
Panel (F) shows representative H&E staining of livers (10x) from each group. Total lipids (G) and triglyceride (H) per gram of muscle section were
also determined (CON, n = 9; NAR n = 9). Values are presented as mean ± SEM. Significance between groups was determined by Student’s t test.
#P < 0.05 compared CON with NAR.
Ke et al. Nutrition & Metabolism 2015, 12:1 Page 6 of 10
http://www.nutritionandmetabolism.com/content/12/1/1reduced lipid content in skeletal muscle, we measured the
mRNA levels of genes involved in fatty acid metabolism
(Figure 4C). However, naringenin had no effect on the ex-
pression of Cpt1β and PGC1α in muscle. Interestingly,
Fasn mRNA expression was higher in muscle tissue of
NAR relative to CON mice but did not reach significance
(p = 0.07).
Discussion
Estrogen deficiency leads to metabolic changes and in-
creased risk of metabolic syndrome [1-3,30]. To our
knowledge, this is the first paper to examine the effects of
naringenin on energy metabolism and adiposity in OVX
female mice, a preclinical model of menopause. We report
here that OVX mice exhibited metabolic disturbances ex-
pected with estrogen deficiency including elevated fasting
glucose and obesity [3,26,31]. The addition of naringenin
to the diet 1) decreased body weight, fasting glucose and
insulin, 2) reduced body fat and perigonadal adipose tissue
inflammation, 3) decreased plasma cholesterol and ectopic
lipid accumulation in liver and muscle, and 4) affectedexpression of hepatic genes involved in de novo lipogen-
esis and fatty acid oxidation. Therefore, our study results
suggest that a 3% wt/wt dietary naringenin supplementa-
tion ameliorates many metabolic derangements associated
with estrogen deficiency.
We observed that naringenin supplementation caused
an initial reduction of caloric intake, followed by a de-
crease in caloric intake and body weight over the subse-
quent ten weeks of feeding. Reduced caloric intake after
naringenin supplementation in the present study was un-
expected because previous studies had reported no differ-
ences in food intake in male rodent models supplemented
with naringenin [11-13,32-34]. No changes in food in-
take were observed even in the same strain, wild-type
C57BL/6 J males [12,35]. Discrepancies between our
data from studies in C57BL/6 J males may be attributed
to the fat content in the diet, age of the mice, and differ-
ent effects of naringenin on appetite between male and
female OVX mice.
Estrogen interacts with neuropeptides, decreases food
intake, and reduces weight gain [36]. Hyperphagia has
Figure 4 Effects of dietary naringenin on gene expression in
liver and muscle. mRNA expression of hepatic genes related to de
novo lipogenesis and hepatic steatosis (A), mRNA expression of
hepatic genes related to beta-oxidation and gluconeogenesis (B),
and mRNA expression of genes related to de novo lipogenesis
and beta-oxidation in muscle (C) were quantified using qRT- PCR
(n = 6-10/group). Values are presented as mean ± SEM. Significance
between groups was determined by Student’s t test. #P < 0.05
compared CON with NAR.
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not all [17,36-38]. Instead of altering food intake, several
studies demonstrated that OVX mice have lower energy
expenditure and activity levels, especially in the dark
phase of the light/dark cycle [17,37-39]. These findings
are consistent with human data demonstrating decreased
free-living and 24 h energy expenditure, and reducedphysical activity during the menopausal transition [40].
The totality of evidence suggests that reduced energy ex-
penditure and increased energy efficiency, rather than
overeating, results in the menopause-associated metabolic
disturbances. We did not observe differences in spontan-
eous physical activity and in energy expenditure between
groups after controlling for body weight. It is unclear
whether the effects of naringenin on body weight and
other OVX-related metabolic disturbances are attributed
to reduced caloric intake and/or other mechanisms. In fu-
ture studies, a pair-fed group will be included to control
for possible differences in energy intake as a potential con-
founding factor.
Dietary naringenin attenuated hyperglycemia and hyper-
insulinemia induced by a high-fat or a fructose-enriched
diet [12,33]. We observed development of hyperglycemia
in OVX mice from week 5 to week 18, consistent with
Roger et al. who showed elevated fasting glucose in mice
after 12 weeks of ovariectomy compared to sham-operated
mice [16], while naringenin supplementation prevented the
development of hyperglycemia and lowered fasting insulin
concentration and HOMA-IR value. Potter et al. suggest
that a significant difference in insulin resistance (deter-
mined by insulin tolerance test) may not develop until as
late as 26 weeks post-ovariectomy [17], which may explain
why insulin reduced blood glucose levels more effectively
in mice supplemented with naringenin but the glucose
AUC did not reach significance in the present study.
Estrogen deficiency increases the susceptibility to weight
gain and central obesity in both humans and mice
[11,16,41]. Hong et al. demonstrated that adiposity in
OVX female mice, examined by DEXA, were comparable
with those of male mice [42]. Additionally, despite con-
suming a low-fat diet, the OVX mice accumulated about
40% body fat and about a 25% reduction in percent body
fat after undergoing a 30% calorie restriction [42]. Simi-
larly, we found that OVX mice accumulated about 40% of
body fat as assessed by MRI. Although naringenin reduced
caloric intake by ~14%, total adiposity decreased by ap-
proximately 50%. Additionally, naringenin significantly
reduced perigonadal adipose tissue mass, even after con-
trolling for body weight. Dietary naringenin has been
linked to decreased adiposity in several male mouse
studies independent of caloric intake [12,34,35]. Such data
further suggest that the effect of naringenin on adiposity
is not simply attributable to lower caloric intake.
Increased visceral fat and pro-inflammatory activity
have been observed in postmenopausal women [43,44].
Previous studies indicate adipose tissues inflammation
occurred early in OVX mice (e.g., 12 weeks after ovari-
ectomy) and progressively worsens as indicated by in-
creased infiltration and activation of immune cells and
decreased insulin sensitivity [16,17]. Genetic deletion of
MCP1 reduces body fat, increases glucose tolerance, and
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OVX mice, but has no effect on sham-operated mice.
These findings suggest that MCP1 may be a mediator of
OVX-induced metabolic disturbances attributed to adi-
pose tissue inflammation [45]. Yoshida et al. demon-
strated that naringenin inhibited high-fat-diet induced
toll-like receptor 2 mRNA expression and suppressed
mRNA levels of proinflammatory mediators, TNFα and
MCP1, in epididymal/perigonadal adipose tissue [35].
We found that naringenin down-regulated mRNA levels
of MCP1 but not TNFα in perigonadal fat. Future
studies will investigate the mechanisms of naringenin ac-
tion on adipose tissue inflammation of OVX mice.
Interestingly, we found that naringenin significantly
reduced MCP1 and IL6 mRNA in perigonadal adipose
tissue, but had no significant effect on these markers of
inflammation in subcutaneous adipose tissue. Rogers
et al. [16] suggested that adipose tissue inflammation as-
sociated with OVX is more severe in perigonadal adi-
pose tissue than in subcutaneous adipose tissue, which
may explain why we found a more significant effect of nar-
ingenin on perigonadal adipose tissue inflammation. Add-
itionally, by LC/MS-MS analyses, naringenin accumulated
1.7 fold more in perigonadal adipose than in subcutaneous
adipose tissue after 11 weeks of 3% naringenin supple-
mentation (3.03 ± 2.00 μmole/kg vs. 5.11 ± 1.26 μmole/kg,
data unpublished), suggesting that naringenin may have
less influence on subcutaneous adipose tissue.
Estrogen deficiency has been connected to hepatic fat
accumulation in women and rodents [3,26]. In the present
study, we demonstrated that naringenin supplementation
led to decreased hepatic lipid accumulation and changed
mRNA levels of some genes involved in de novo lipogen-
esis and fatty acid oxidation. Several studies have shown
that naringenin induces PPARα activity and downstream
enzymes involved in fatty acid oxidation, such as CPT1α,
UCP2, and ACOX1 [11,13]. Interestingly, we observed in-
creased Cpt1α mRNA levels but decreased Acox1 levels,
implicating discordance in mitochondrial and peroxisomal
β-oxidation in response to OVX and naringenin treat-
ment. Goldwasser et al. [14] also showed that naringenin
induced a fasted-like state in hepatocytes, inhibiting fatty
acid and cholesterol synthesis and increasing fatty acid
oxidation. Consistent with these in vitro results, we also
observed increased Srebf1 and PGC1α mRNA in the liver
of mice supplemented with naringenin. However, we did
not observe increased expression microsomal triglyceride
transfer protein (Mttp) expression and were unable to
detect low-density lipoprotein (LDL) receptor mRNA ex-
pression (data not shown), which are downstream genes
of Srebf1 and inducible by naringenin in vitro [46]. Add-
itionally, we found increased hepatic expression of genes
controlling gluconeogenesis in the mice fed naringenin, a
normal physiological reaction in response to fasting. Lackof induction of these two genes in the CON mice may be
related to their high levels of fasting glucose.
We demonstrated that naringenin decreased plasma
cholesterol but did not change the levels of plasma tria-
cylglyceride and non-esterified fatty acids in OVX mice.
However, the effects of OVX on blood triacylglyceride
and non-esterified fatty acids are mixed. Several studies
have shown no difference in blood triacylglyceride and
non-esterified fatty acids between sham-operated and
OVX rodents [16,17,39,47-49], while others have observed
increased levels in OVX rodents [27,50]. It is possible that
OVX had no effect on triacylglyceride and non-esterified
fatty acids in the current study. Therefore we did not ob-
serve changes in plasma triacylglyceride and non-esterified
fatty acids in naringenin-supplemented mice.
Estrogen deficiency-associated metabolic disturbances
have been widely demonstrated in OVX mice [16,17,37,
39,40,42,51]. There were several limitations of the present
study. Due to the atrophy of the uterus observed in our
OVX mice, we could not measure the weight of uterus to
determine whether there is an estrogenic or anti-estrogenic
effect of naringenin. Additionally, we did not have sham-
operated mice as a control to evaluate the degrees of meta-
bolic disturbances in our OVX mice and thus the extent of
naringenin effects. However, the elevated fasting glucose,
adiposity, and hepatic lipid accumulation observed in OVX
mice in the present study were markedly reduced with nar-
ingenin supplementation. In addition, as mentioned earlier,
we did not design this study to include a pair-fed group
since previous studies evaluating metabolic effects of diets
with naringenin in male rodents did not observe differ-
ences in food intake.
Naringenin readily accumulates in plasma after inges-
tion of orange juice, grapefruit juice [52], and tomato
paste or sauce [53], suggesting that it is bioavailable in in-
dividuals who consume naringenin food sources regularly.
In the present study, we found that mice developed higher
fasting glucose, adiposity, and hepatic steatosis after loss
of ovarian function, similar to what has been observed in
postmenopausal women [3,31]. Naringenin supplemen-
tation attenuated these estrogen-deficiency-associated
metabolic disturbances in OVX female mice, suggesting
the potential influence of dietary naringenin on meta-
bolic syndrome in postmenopausal women. Further
work in pre-clinical and human intervention studies will
help to determine if naringenin is able to protect against
menopausal-associated metabolic syndrome in humans.Additional file
Additional file 1: Table S1. Composition of experimental diets. Table
S2: Real-time PCR primers and probes of Taqman gene expression assay.
Figure S1: Illustration of different fat depots analyzed in the present
paper. Total, intra-abdominal, and subcutaneous adiposity were analyzed
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http://www.nutritionandmetabolism.com/content/12/1/1by MRI using a Bruker Biospin 94/30 magnet (Billerica, MA, USA) and a 70
mm diameter linear volume coil. T1-weighted coronal images of the
whole mouse torso were collected using a respiratory-gated RARE
sequence (TR/TE=1570/7.5ms, RARE factor=4, FOV=70x45 mm2, matrix
size=256x192, slice thickness=1 mm, navg=2). Mice were anesthetized
with 2-2.5% isoflurane mixed with 1 liter per minute carbogen (95%O2+
5%CO2) and maintained with 1-1.5% isoflurane. Physiologic parameters
such as the electrocardiography, respiration and the temperature of
the animals were monitored using a small animal monitoring system
(Model 1025, Small Animals Instruments, Inc. Stony Brook, NY, USA).
Otsu segmentation [1] was used to segment the mouse body from
background. A connected components algorithm [2] was used to label the
background objects in the image and ‘fill’ any holes in the segmented body
image. The abdominal cavity was manually outlined in the images and a
global threshold of 120 grey level intensity was chosen to segment fat from
surrounding tissue. The whole body and abdominal masks were then used
to calculate the percentage of segmented voxels in the whole body and
abdomen, respectively. Subcutaneous fat was calculated by subtracting
intra-abdominal fat from total fat. Figure S2: Insulin tolerance test was
performed at week 21 to determine insulin sensitivity (CON, n=4; NAR n=5).
After a 5h-fast, insulin was administered intraperitoneally at a dose of 0.4
U/kg body weight (Humulin R, Eli Lilly and Co., Indianapolis, IN, USA).
Glucose was measured from tail vein blood using a OneTouch Ultra blood
glucose meter immediately prior to insulin injection (time 0) and 15, 30, 45,
60, 90, and 120 minutes following the injection. The values were normalized
to baseline (time 0) values and the percent change from baseline was
plotted over time. The response curve was used to calculate area under the
curve (AUC) [3]. Graphical representation of the calculated area under curve
(AUC) between time point 0 to 120 min was shown on the top right.
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